Relationship of Body Weight to Maintenance Cyclosporine A Dose in Canine Atopic Dermatitis

Abstract

Cyclosporine A (CsA) is a commonly prescribed and effective therapy for canine atopic dermatitis. The purpose of this study was to investigate the potential relationship between patient body weight and CsA dosing. Seventy-seven cases of canine atopic dermatitis managed between 2000 and 2011 were evaluated retrospectively. Duration of CsA therapy was at least 16 wk. Groups analyzed included the study population as a whole, those treated with only CsA, and those treated with both CsA and metoclopramide. The division between small and large dogs was set at 15 kg. Descriptive analysis, two-way analysis of variance, Pearson correlations, and a Student t test were used to analyze data. There were no significant differences between CsA dose and body weight regardless of method of analysis. Concurrent corticosteroid use, other medication use, and pruritus score were also analyzed over the study period. There was a significant decrease in CsA dose, corticosteroid dose, medication score, and pruritus score between the time points for all patients, but no significant relationship between those changes and body weight. These study findings suggest that differential CsA dosing is not warranted based on body weight.